The ASAM Review Course in Addiction Medicine 2019 (20.5 CME)

4.8 (30 votes)

  • Register
    • Non-Member - $599
    • Regular Member - $449
    • Retired - $449
    • Early Career Physician - $449
    • Resident - $299
    • Student - $299
    • Associate - $299
    • ASAM Staff - Free!
    • International Member - $449
    • Emeritus Member - $449
    • Provisional Member - $449
    • Fellow Member - $449
    • Honorary Member - $449
    • CRT Member - $449
image

Overview

The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

The course offers recorded sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

Learning Objectives

Upon completion, participants should be able to:

  1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
  2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
  3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
  4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
  5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

Additional Resources

Additional Board Exam Preparation resources and tools are also available.


 

  • Board Exam Practice Questions & Expert Panel Discussion (4.25 CME)

    Contains 8 Component(s), Includes Credits

    Earn 4.25 AMA PRA Category 1 Credits while watching an expert panel reviews questions from the attendees of The ASAM Review Course in Addiction Medicine 2018.

    (4.25 CME) In this session recording from The ASAM Review Course in Addiction Medicine 2019, an expert panel reviews questions from the attendees of The ASAM Review Course in Addiction Medicine 2019

  • Session 10: Epidemiology (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about epidemiological concepts and trends that are important for the ABPM Addiction Medicine Exam in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about epidemiological concepts and trends is valuable both for acing the ABPM Addiction Medicine exam as well as for honing one's identity as an expert in addictions.  This talk will help frame the domains of study that are important for the ABPM examination and how to consider studying/reviewing these concepts.   A few key epidemiological concepts will be reviewed in detail to refresh one's thinking about epidemiological concepts. In addition, up-to-date trends in national substance use patterns will be reviewed.  The presenter is not a "certified" epidemiologist, so concepts will be discussed in a manner to maximize accessibility to non-experts, like himself.

    Jeffrey J. DeVido

    MD, MTS, FASAM

    Jeffrey J. DeVido, MD, MTS, FASAM
    Affiliation: Chief, Addiction Services and Assistant Clinical Professor, Psychiatry
    Marin County California and University of California San Francisco 

    Dr. DeVido earned a Masters in Theological Studies from Harvard Divinity School, completed his medical schooling at Columbia University College of Physicians and Surgeons and adult psychiatry and addiction psychiatry training at Massachusetts General/McLean Hospitals.  In 2013, Dr. DeVido joined the faculty of UCSF as assistant professor working in consultation liaison psychiatry at the Parnassus Medical Center where he provided psychiatric evaluation and management of patients presenting to the emergency room and medical/surgical/intensive care units with co-occurring mental and medical illnesses.  He is a member of the board of directors of the American Academy of Addiction Psychiatry and sits on the American Psychiatric Association’s Council on Addictions, and he remains on faculty at UCSF.  He holds board certification in adult psychiatry, addiction psychiatry, and addiction medicine and he has published on a wide range of topics including issues related to medication assisted treatment and management of substance use disorders in pregnancy.  He recently joined the Department of Health and Human Services, Behavioral Health and Recovery Services in Marin County, CA, as the Chief of Addiction Services. 

  • Session 1: Neurobiology of Addiction (1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about motivational circuitry, anti-reward pathways and interoception in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (1 CME) In this recording from the 2019 Review Course, you will learn about the neurobiology of addiction medicine. From a neurobiological perspective, addiction can be seen as the hijacking of the pleasure-reward pathways of the brain with a concomitant weakening of its executive function. In 2019, the fundamental model has been expanded to include newer ideas such as motivational circuitry, anti-reward pathways, and interoception. These neurobiological concepts can explain some of the successes and failures of addiction treatment in the second half of the 20th century and the beginning of the 21st century. Psychosocial interventions (primarily cognitive behavior therapy, mutual help groups, and motivational interviewing) and pharmacological treatments (such as agonists, antagonists, and partial agonists) form the basis of addiction treatment today.

    Petros Levounis

    MD, MA, DFASAM

    Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he received an MA degree in sociology from Stanford before moving to New York City where he trained in psychiatry at Columbia University. He graduated from Columbia receiving the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University. From 2002 to 2013, he served as director of the Addiction Institute of New York.
    Dr. Levounis has written numerous articles and monographs; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by all major television networks. Dr. Levounis serves on the Board of Directors of the American Society of Addiction Medicine (ASAM) and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association. Dr. Levounis is a Betty Ford Scholar, a recipient of a U.S. State Department Speaker and Specialist Award, a distinguished fellow of the APA and ASAM, and an honorary member of the World Psychiatric Association. 

    Dr. Levounis has published thirteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “The Behavioral Addictions,” “Motivational Interviewing for Clinical Practice,” “Becoming Mindful,” and the “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition. His books have been translated into German, Hungarian, Japanese, Portuguese, and Spanish. 

    Dr. Levounis is married to actor Lukas Hassel and lives in New York City.

    ACCME Accredited with Commendation

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM MOC LLSA Statement

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification Program(tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1AMA PRA Category 1 Credit(s)™ for completing this enduring material.

  • Session 2: Alcohol (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about screening for alcohol use disorder, alcohol withdrawal management and Relapse Prevention Medications in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about  the basic concepts of alcohol use disorder: Standard drink sizes, screening for alcohol use disorder, an introduction to alcohol withdrawal management and the use of Relapse Prevention Medications

    Jill M. Williams

    MD

    Jill M. Williams MD
    Affiliation: Professor of Psychiatry and Director of the Division of Addiction Psychiatry
    Rutgers University-Robert Wood Johnson Medical School

    Jill M. Williams, MD, is Professor of Psychiatry and Director of the Division of Addiction Psychiatry at the Rutgers University-Robert Wood Johnson Medical School in New Brunswick. She also holds faculty appointments at the Cancer Institute of New Jersey and the Rutgers Center for Addiction Studies. The focus of Dr. Williams work has been in addressing tobacco in individuals with mental illness or other addictions through treatment and systems interventions. Dr Williams has developed training curricula for behavioral health professionals and manualized treatments for treating tobacco in mental health settings.  She is a Board Certified Addiction Psychiatrist and member of the APA Council on Addictions. Dr. Williams has received research funding from sources including the National Institutes on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and American Legacy Foundation. Her publications have appeared in numerous journals including Nicotine and Tobacco Research, the Journal of the American Medical Association, and the Journal of Substance Abuse Treatment and in 2015 she was the recipient of the Remarkable Achievement Award of the NJ Psychiatric Association. 

  • Session 3: Sedatives (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about withdrawal from sedatives, benzodiazepines, barbiturates and GHB in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about the basic concepts of sedative use disorder: Neurobiology, an introduction to sedative withdrawal and the use of clinical strategies to address intoxication and withdrawal of benzodiazepines, barbiturates and GHB.

    Jill M. Williams

    MD

    Jill M. Williams MD
    Affiliation: Professor of Psychiatry and Director of the Division of Addiction Psychiatry
    Rutgers University-Robert Wood Johnson Medical School

    Jill M. Williams, MD, is Professor of Psychiatry and Director of the Division of Addiction Psychiatry at the Rutgers University-Robert Wood Johnson Medical School in New Brunswick. She also holds faculty appointments at the Cancer Institute of New Jersey and the Rutgers Center for Addiction Studies. The focus of Dr. Williams work has been in addressing tobacco in individuals with mental illness or other addictions through treatment and systems interventions. Dr Williams has developed training curricula for behavioral health professionals and manualized treatments for treating tobacco in mental health settings.  She is a Board Certified Addiction Psychiatrist and member of the APA Council on Addictions. Dr. Williams has received research funding from sources including the National Institutes on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and American Legacy Foundation. Her publications have appeared in numerous journals including Nicotine and Tobacco Research, the Journal of the American Medical Association, and the Journal of Substance Abuse Treatment and in 2015 she was the recipient of the Remarkable Achievement Award of the NJ Psychiatric Association. 

  • Session 4: Opioids (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about botany and composition of opioids, opioid receptors and endogenous ligands in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about botany and the composition of opium and it's alkaloids.The basic science of the opioid receptors and their endogenous ligands will be reviewed. Physiologic effects and adverse effects, including withdrawal and overdose syndromes will be described. Comprehensive treatment of opioid use disorder will be explained.

    Edwin A. Salsitz

    MD, DFASAM

    Edwin A. Salsitz, MD, FASAM
    Affiliation: Associate Clinical Professor
    Mount Sinai Beth Israel

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel, Division of Chemical Dependency, New York City since 1983 and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics. Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the co-chair of the ASAM CME committee and chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award and the 2018 ASAM Annual Educator of the Year Award.

  • Session 5: Tobacco (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about nicotine use disorder and various treatment options in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about the epidemiology and health consequences of tobacco use. It will review the pharmacology of nicotine and the clinical manifestations of nicotine use disorder and compare various treatment options. It will also discuss the current evidence regarding electronic cigarettes.

    Annie Levesque

    MD, MSc

    Annie Levesque, MD, MSc
    Affiliation: Medical Director and Assistant Professor of Psychiatry
    Mount Sinai West Hospital

    Dr. Annie Levesque is the Medical Director of the Opioid Treatment Program at the Addiction Institute at Mount Sinai West. She is also the Associate Director of the Fellowship in Addiction Medicine Program at the Icahn School of Medicine at Mount Sinai. After receiving her medical degree from the University of Montreal, Dr. Levesque completed a Family Medicine and a Clinician-Scholar residency program at the University of Montreal, an Addiction Medicine fellowship at Mount Sinai West Hospital and a Masters in Experimental Medicine at McGill University.

  • Session 6: Cannabis (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about diagnosis and treatment considerations for cannabis in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about the epidemiology, background on the substance, pharmacokinetics and pharmacodynamics, diagnosis, and treatment considerations for cannabis and substances that act on the cannabinoid system.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD
    Affiliation: Associate Professor of Psychiatry
    University of California, San Diego

    Carla Marienfeld, MD, is a board-certified addiction psychiatrist and Associate Professor at the University of California, San Diego who supports recovery through therapy, motivational interviewing, and medication treatment. Her research looks at health outcomes for individuals with substance use disorders, and she published a book Motivational Interviewing for Clinical Practice. She has been highly involved in education of colleagues and trainees about addiction psychiatry and effective interventions including buprenorphine treatment and motivational interviewing, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led) the Yale Global Mental Health Program as junior faculty at Yale. She earned a medical degree with honors from Baylor College of Medicine in Houston.

  • Session 7: Stimulants (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about pharamlogical effects and molecular mechanisms of action for absued stimulant drugs in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about methods of use, pharmacological effects, and molecular mechanisms of action for abused stimulant drugs, including cocaine, methamphetamine and newer "bath salts" cathinones.  Clinical approaches for treating adverse effects and stimulant use disorders will be discussed.

    Michael H. Baumann

    PhD

    Miachael H. Baumann, PhD
    Affiliation: Chief, Designer Drug Research Unit 
    National Institute on Drug Abuse and National Institutes of Health

    Michael H. Baumann, Ph.D. is a Staff Scientist and Chief of the Designer Drug Research Unit (DDRU), at the Intramural Research Program (IRP) of the National Institute on Drug Abuse (NIDA) in Baltimore, Maryland.  The DDRU collects, analyzes and disseminates the most up-to-date information about the pharmacology and toxicology of newly-emerging synthetic drugs of abuse (i.e., designer drugs), more formally known as new psychoactive substances (NPS).  Working with partner organizations such as the Drug Enforcement Administration (DEA) and the National Drug Early Warning System (NDEWS), Dr. Baumann is kept informed about trends in the misuse of NPS.  The DDRU has characterized the molecular mechanism of action and pharmacological effects for a diversity of NPS, including “bath salts” (synthetic stimulants), “spice” (synthetic cannabinoids) and synthetic opioids.  Findings from the DDRU inform law enforcement personnel, health care workers, clinical toxicologists, forensic scientists, basic researchers, and policymakers who are involved in responding to the global spread of NPS and the associated public health risks. 

  • Session 8: Other Classes of Drugs (.75 CME)

    Contains 3 Component(s), Includes Credits

    Earn .75 AMA PRA Category 1 Credit(s)™ while learning about hallucinogens, dissociatives, inhalants and steroids in this recording from The ASAM Review Course in Addiction Medicine (2019).

    (.75 CME) In this recording from the 2019 Review Course, you will learn about a diverse group of substances including hallucinogens, dissociatives, inhalants and steroids.  The physiological effects and epidemiology will be presented, along with notable examples of each class.  Features of specific substance use disorders as well as treatment options will also be discussed.

    Abigail J. Herron

    DO, DFASAM, FAPA

    Abigail J. Herron, DO, DFASAM, FAPA
    Affiliation: Director of Psychiatry and Director of the Fellowship in Addiction Medicine
    Institute for Family Health

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  

    Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  

    Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ASAM CME Committee and Reviewers Disclosure Listing

First Name Commercial Interests Compensation Received For what Role?
Timothy Brennan MD, MPH, FASAM None
Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
James Finch MD, DFASAM None

Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
Adam Gordon, MD, MPH None
Leslie Hayes, MD None
Abigail Herron DO, DFASAM None
Petros Levounis MD, MA, FASAM None
Carla Marienfeld MD None
Ricardo Restrepo MD, MPH, FASAM None
Richard Ries MD, DFASAM None
Edwin Salsitz MD, DFASAM None
Sharon Stancliff MD, FASAM None
Timothy Wiegand MD, FACMT, FAACT None
Erin Zerbo, MD None
ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (tMOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.

Upon completion, participants should be able to:

  1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
  2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
  3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
  4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
  5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.

The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

  • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
  • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
  • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients